Yung Lyou, MD, discusses FDA-approved isotope therapies and the development of novel therapies in the castration-resistant prostate cancer space.
Fawzi F Abu Rous, MD, discusses ongoing efforts to address unmet needs in the management of squamous cell carcinoma of the lung.
Nerea Lopetegui-Lia, MD, discusses ongoing trials investigating ADCs that are shaking up the metastatic triple-negative breast cancer setting.
Fiona Simpkins, MD, discusses the use of cyclin E1 positivity as a biomarker of azenosertib response in platinum-resistant ovarian cancer.
Isabel Preeshagul, DO, MBS, discusses the need for a nuanced approach when selecting between targeted therapies in ALK- and EGFR-altered NSCLC.
Bradley Monk, MD, FACOG, FACS, discusses the FDA’s accelerated approval of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.
Marc R. Matrana, MD, discusses the evolving frontline treatment landscape for advanced metastatic prostate cancer.
Evan Y. Yu, MD, discusses PARP inhibitor treatment selection and sequencing for patients with metastatic castration-resistant prostate cancer.
Evan Y. Yu, MD, discusses future directions for biomarker research and targeted therapy development for patients with castration-resistant prostate cancer.
A sBLA for nogapendekin alfa inbakicept in BCG-unresponsive non–muscle-invasive bladder cancer with papillary disease was submitted to the FDA.
Juan Carlos Hernández-Boluda, MD, PhD, discusses the development of an EBMT machine learning model for predicting allo-HCT risk in myelofibrosis.
